# OnCo record chemo-io-then-maintenance-sclc (pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pairings/chemo-io-then-maintenance-sclc/>
  a schema:MedicalTherapy ;
  onco:kind "pairing" ;
  schema:identifier "chemo-io-then-maintenance-sclc" ;
  schema:name "Chemo-immunotherapy induction → maintenance intensification (SCLC)"@en ;
  schema:description "Chemo-immunotherapy followed by maintenance in small-cell lung cancer gives four cycles of chemotherapy plus immunotherapy, then keeps the immunotherapy going and adds a second drug to hold the disease longer."@en ;
  schema:url <https://onco.cc/pairings/chemo-io-then-maintenance-sclc/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05091567>, <https://clinicaltrials.gov/study/NCT06211036> ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/tarlatamab/> ;
  onco:trials <https://onco.cc/trials/imforte/>, <https://onco.cc/trials/dellphi-305/> ;
  onco:pairs <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/lurbinectedin/> .